Life Sciences DNA Podcast podcast

Measuring AI by Business Results in Life Sciences

0:00
54:10
Rewind 15 seconds
Fast Forward 15 seconds

Artificial intelligence is creating new opportunities to improve clinical development, but successful adoption requires more than choosing the latest model or launching isolated pilots. Krishna Cheriath, vice president and head of digital and AI for biopharma services at Thermo Fisher Scientific, sits down with Srivatsan Nagaraja to discuss what it takes to translate AI’s promise into measurable business and patient impact, why companies should focus on a small number of strategic imperatives, and his practical approach for prioritizing high-value use cases.

More episodes from "Life Sciences DNA Podcast"